Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study.
暂无分享,去创建一个
J. Verweij | L. Dirix | D. Wagener | M. Buitenhuis | A. Mathieu-Boué | G. Catimel | P. Siegenthaler | H. Verdonk | D. Wagener
[1] T. Chou,et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] P. Hérait,et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. , 1994, Journal of the National Cancer Institute.
[3] P. Hérait,et al. High dose intensity of CPT-11 administered as single dose every 3 weeks: The instittut gustave roussy experience , 1993 .
[4] M. Fukuoka,et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Y. Nishiwaki,et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Ohno,et al. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] T. Furuta,et al. [Antitumor activity of CPT-11 against rat Walker 256 carcinoma]. , 1988, Gan to kagaku ryoho. Cancer & chemotherapy.
[8] T. Tanaka,et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. , 1987, Cancer research.
[9] J. Petrek,et al. Can survival in pancreatic adenocarcinoma be predicted by primary size or stage? , 1985, The American surgeon.
[10] F. Glenn,et al. Carcinoma of the Pancreas , 1941 .